[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565569":3},{"organization":4,"armGroups":7,"interventions":41,"overallOfficials":56,"centralContacts":60,"locations":65,"responsibleParty":170,"collaborators":32,"id":172,"slug":32,"hasResults":173,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":32,"eligibilityCriteria":177,"healthyVolunteers":173,"sex":178,"minAge":179,"maxAge":32,"enrollmentInfo":180,"targetDuration":32,"studyType":183,"phases":184,"briefSummary":186,"conditions":187,"keywords":190,"overallStatus":68,"whyStopped":32,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":204},{"fullName":5,"class":6},"Aura Biosciences","INDUSTRY",[8,16,20,24,28,33,37],{"label":9,"type":10,"description":11,"interventionNames":12},"80 micrograms of bel-sar","EXPERIMENTAL","1 Cycle AU-011 with a dose of 80 micrograms",[13,14,15],"Drug: AU-011","Device: SCS Microinjector","Device: Laser",{"label":17,"type":10,"description":18,"interventionNames":19},"140 micrograms of bel-sar","1 Cycle AU-011 with a dose of 140 micrograms",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"200 micrograms of bel-sar with one cycle","1 Cycle AU-011 with a dose of 200 micrograms",[13,14,15],{"label":25,"type":10,"description":26,"interventionNames":27},"200 micrograms of bel-sar with two cycles","2 Cycles AU-011 with a dose of 200 micrograms",[13,14,15],{"label":29,"type":30,"description":31,"interventionNames":32},"Observational","NO_INTERVENTION","Subjects that meet trial inclusion, but do not meet criteria for enrollment into the bel-sar treatment cohorts, may be enrolled in this cohort. The observational cohort will not receive bel-sar treatment.",null,{"label":34,"type":10,"description":35,"interventionNames":36},"40 micrograms of bel-sar with one cycle","1 Cycle AU-011 with a dose of 40 micrograms",[13,14,15],{"label":38,"type":10,"description":39,"interventionNames":40},"40 micrograms of bel-sar with two cycles","2 Cycles AU-011 with a dose of 40 micrograms",[13,14,15],[42,47,52],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":32},"DRUG","AU-011","AU-011 Via Suprachoroidal Administration with laser treatment",[17,21,25,34,38,9],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":32},"DEVICE","SCS Microinjector","Suprachoroidal Injection Device",[17,21,25,34,38,9],{"type":48,"name":53,"description":54,"armGroupLabels":55,"otherNames":32},"Laser","Laser Administration",[17,21,25,34,38,9],[57],{"name":58,"affiliation":5,"role":59},"Medical Monitor","STUDY_DIRECTOR",[61],{"name":58,"role":62,"phone":63,"phoneExt":32,"email":64},"CONTACT","617-500-8864","clinical@aurabiosciences.com",[66,79,89,99,109,120,130,140,150,160],{"facility":67,"status":68,"city":69,"state":70,"zip":71,"country":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":32},"Byers Eye Institute at Stanford University","RECRUITING","Palo Alto","California","94303","United States",{"type":74,"coordinates":75},"Point",[76,77],-122.14302,37.44188,{"lat":77,"lon":76},{"facility":80,"status":68,"city":81,"state":82,"zip":83,"country":72,"cosmosGeoPoint":84,"geoPoint":88,"contacts":32},"Bascom Palmer Eye Institute","Miami","Florida","33136",{"type":74,"coordinates":85},[86,87],-80.19366,25.77427,{"lat":87,"lon":86},{"facility":90,"status":68,"city":91,"state":92,"zip":93,"country":72,"cosmosGeoPoint":94,"geoPoint":98,"contacts":32},"Massachusetts Eye and Ear","Boston","Massachusetts","02114",{"type":74,"coordinates":95},[96,97],-71.05977,42.35843,{"lat":97,"lon":96},{"facility":100,"status":68,"city":101,"state":102,"zip":103,"country":72,"cosmosGeoPoint":104,"geoPoint":108,"contacts":32},"Kellogg Eye Center","Ann Arbor","Michigan","48105",{"type":74,"coordinates":105},[106,107],-83.74088,42.27756,{"lat":107,"lon":106},{"facility":110,"status":111,"city":112,"state":113,"zip":114,"country":72,"cosmosGeoPoint":115,"geoPoint":119,"contacts":32},"Mayo Clinic","NOT_YET_RECRUITING","Rochester","Minnesota","55905",{"type":74,"coordinates":116},[117,118],-92.4699,44.02163,{"lat":118,"lon":117},{"facility":121,"status":111,"city":122,"state":123,"zip":124,"country":72,"cosmosGeoPoint":125,"geoPoint":129,"contacts":32},"Cleveland Clinic, Cole Eye Institute","Cleveland","Ohio","44195",{"type":74,"coordinates":126},[127,128],-81.69541,41.4995,{"lat":128,"lon":127},{"facility":131,"status":111,"city":132,"state":133,"zip":134,"country":72,"cosmosGeoPoint":135,"geoPoint":139,"contacts":32},"Shields and Shields, PC","Philadelphia","Pennsylvania","19107",{"type":74,"coordinates":136},[137,138],-75.16362,39.95238,{"lat":138,"lon":137},{"facility":141,"status":68,"city":142,"state":143,"zip":144,"country":72,"cosmosGeoPoint":145,"geoPoint":149,"contacts":32},"Tennessee Retina, PC","Nashville","Tennessee","37203",{"type":74,"coordinates":146},[147,148],-86.78444,36.16589,{"lat":148,"lon":147},{"facility":151,"status":68,"city":152,"state":153,"zip":154,"country":72,"cosmosGeoPoint":155,"geoPoint":159,"contacts":32},"Retina Consultants of Texas","Bellaire","Texas","77401",{"type":74,"coordinates":156},[157,158],-95.45883,29.70579,{"lat":158,"lon":157},{"facility":161,"status":68,"city":162,"state":163,"zip":164,"country":72,"cosmosGeoPoint":165,"geoPoint":169,"contacts":32},"University of Washington","Seattle","Washington","98104",{"type":74,"coordinates":166},[167,168],-122.33207,47.60621,{"lat":168,"lon":167},{"type":171,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100565569",false,"NCT06643884","Suprachoroidal Administration in Subjects With Metastases to the Choroid","A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid","Inclusion Criteria:\n\n* Have a clinical diagnosis of Metastases to the Choroid, from a histopathologically or cytologically confirmed tumor.\n* Have at least one Metastases to the Choroid in the study eye\n\nExclusion Criteria:\n\n* Active ocular infection or disease.\n* Must not have evidence of a primary tumor or metastatic lesion in the brain requiring treatment with radiation therapy per the primary treating oncologist's assessment.\n* Must not be planning or expecting to switch\u002Fadd systemic antineoplastic therapies during treatment","ALL","18 Years",{"count":181,"type":182},24,"ESTIMATED","INTERVENTIONAL",[185],"PHASE2","The primary objective is to assess the safety and tolerability of bel-sar treatment in subjects with metastases to the choroid from any primary solid tumor.",[188,189],"Eye Cancer","Primary Cancer",[191,192,193,194],"Choroidal Metastasis","Metastases to the Choroid","ocular","eye","2026-03-11",{"date":197,"type":198},"2026-03-13","ACTUAL",{"date":200,"type":198},"2024-12-16",{"date":202,"type":182},"2027-10-31",{"name":5,"class":6},10]